Pro-Dex (NASDAQ:PDEX) Stock Passes Above Two Hundred Day Moving Average - Here's Why

Pro-Dex, Inc. (NASDAQ:PDEX - Get Free Report)'s share price crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $35.47 and traded as high as $35.53. Pro-Dex shares last traded at $34.56, with a volume of 6,214 shares.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the stock. StockNews.com lowered shares of Pro-Dex from a "strong-buy" rating to a "buy" rating in a report on Monday, February 3rd. Ascendiant Capital Markets lifted their price objective on shares of Pro-Dex from $30.00 to $52.00 and gave the company a "buy" rating in a research note on Monday, November 11th.

Pro-Dex Trading Up 2.5 %

The stock has a market cap of $115.47 million, a price-to-earnings ratio of 17.62 and a beta of 0.53. The business's fifty day simple moving average is $44.03 and its 200 day simple moving average is $35.79. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.58 and a quick ratio of 1.44.

Pro-Dex (NASDAQ:PDEX - Get Free Report) last released its quarterly earnings data on Thursday, January 30th. The medical instruments supplier reported $0.61 EPS for the quarter, topping analysts' consensus estimates of $0.38 by $0.23. Pro-Dex had a net margin of 11.06% and a return on equity of 21.68%. On average, research analysts predict that Pro-Dex, Inc. will post 2 EPS for the current year.

Insiders Place Their Bets

In other news, Director Raymond E. Cabillot sold 1,200 shares of the business's stock in a transaction on Friday, January 10th. The shares were sold at an average price of $47.76, for a total transaction of $57,312.00. Following the completion of the transaction, the director now owns 359,646 shares of the company's stock, valued at approximately $17,176,692.96. The trade was a 0.33 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders sold a total of 27,770 shares of company stock valued at $1,239,312 over the last 90 days. 47.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Pro-Dex

A number of hedge funds and other institutional investors have recently modified their holdings of PDEX. EAM Investors LLC bought a new stake in shares of Pro-Dex during the fourth quarter valued at about $1,047,000. O Shaughnessy Asset Management LLC bought a new stake in shares of Pro-Dex during the fourth quarter valued at about $995,000. 683 Capital Management LLC bought a new stake in shares of Pro-Dex during the fourth quarter valued at about $739,000. Ritholtz Wealth Management bought a new stake in shares of Pro-Dex during the fourth quarter valued at about $572,000. Finally, American Century Companies Inc. bought a new stake in Pro-Dex in the fourth quarter worth about $558,000. 15.28% of the stock is currently owned by institutional investors.

Pro-Dex Company Profile

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.